Elevated serum CXCL12 levels (dichotomized by the median value) were associated with a 2-fold increased risk of immunogenicity, although this analysis was restricted to RA patients treated with 4 different anti-TNFα agents [133]. The gene discussed is TNF; the disease is rheumatoid arthritis.